Vir Biotechnology, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03672188
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Vir Biotechnology, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Influenza, Human (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 17